Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
Authors:
- Nicola PersoneniNPNicola Personeni
- Tiziana PressianiTPTiziana Pressiani
- Antonio D’alessioADAntonio D’alessio
- Maria Giuseppina PreteMPMaria Giuseppina Prete
- Silvia BozzarelliSBSilvia Bozzarelli
- Luigi TerraccianoLTLuigi Terracciano
- Arianna Dal BuonoABArianna Dal Buono
- Antonio CapogrecoACAntonio Capogreco
- Alessio AghemoAAAlessio Aghemo
- Ana LleoAna Lleo
- Romano Fabio LutmanRLRomano Fabio Lutman
- Massimo RoncalliMRMassimo Roncalli
Open Access
Abstract
Risk factors for hepatic immune-related adverse events (HIRAEs) in patients with advanced/unresectable hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs) are unclear. We investigated: (i) clinical and morpho-pathological predictors of HIRAEs in 27 pretreatment tumor specimens, including surrogate biomarkers of the HCC immune class (based on intratumoral tertiary lymphoid structures, and glutamine synthase, CD3, and CD79 expression); and (ii) the relationship between HIRAE onset and subsequent treatment outcomes. Fifty-eight patients were included—20 (34%) received ICIs alone, and 38 (66%) received ICIs plus targeted agents as first- or further-line treatment. After a median time of 0.9 months (range, 0.4–2.7), nine patients (15.5%) developed grade ≥ 3 hepatitis, which was significantly associated with higher baseline ALT levels (p = 0.037), and an infectious HCC etiology (p = 0.023). ICIs were safely resumed in six out of nine patients. Time to treatment failure (TTF) was not significantly different in patients developing grade ≥ 3 hepatitis vs. lower grades (3.25 vs. 3.91 months, respectively; p = 0.81). Biomarker surrogates for the HCC immune class were not detected in patients developing grade ≥ 3 hepatitis. Grade ≥ 3 hepatitis has a benign course that does not preclude safe ICI reintroduction, without any detrimental effect on TTF.Keywords
This publication has 39 references indexed in Scilit:
- Hepatocellular carcinomaThe Lancet, 2018
- Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancerJournal for ImmunoTherapy of Cancer, 2017
- Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanomaAnnals of Oncology, 2017
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular FeaturesGastroenterology, 2017
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialThe Lancet, 2017
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI GradeJournal of Clinical Oncology, 2015
- Hepatotoxicity with Combination of Vemurafenib and IpilimumabNew England Journal of Medicine, 2013
- Drug-Induced Liver Injury Network (DILIN) Prospective StudyDrug Safety, 2009